Gongzhizi Y. Gao

No. 157, West 5th Road
Xi'an, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy.

The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy.

Journal: Discover oncology

Published: November 30, 2024

Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: October 14, 2024

Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non-Hodgkin Lymphoma Patients.

Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non-Hodgkin Lymphoma Patients.

Journal: Cancer medicine

Published: July 08, 2024

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.

Journal: HemaSphere

Published: July 03, 2024

Mitochondria-associated programmed cell death: elucidating prognostic biomarkers, immune checkpoints, and therapeutic avenues in multiple myeloma.

Mitochondria-associated programmed cell death: elucidating prognostic biomarkers, immune checkpoints, and therapeutic avenues in multiple myeloma.

Journal: Frontiers in immunology

Published: June 13, 2024

Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.

Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.

Journal: Therapeutic advances in hematology

Published: May 20, 2024

Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.

Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.

Journal: Frontiers in immunology

Published: May 16, 2024

Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma.

Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma.

Journal: Scientific reports

Published: March 13, 2024

KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway.

KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway.

Journal: Journal of cancer research and clinical oncology

Published: January 10, 2024

Risk score constructed with neutrophil extracellular traps-related genes predicts prognosis and immune microenvironment in multiple myeloma.

Risk score constructed with neutrophil extracellular traps-related genes predicts prognosis and immune microenvironment in multiple myeloma.

Journal: Frontiers in oncology

Published: January 04, 2024

Mediastinal gray zone lymphoma: a case report and literature review

Mediastinal gray zone lymphoma: a case report and literature review

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: July 20, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026